• June 24, 2019

Newron Pharmaceuticals to Present at the JMP Securities Life Sciences Conference - Odessa American: Business

e-Edition Subscribe

Newron Pharmaceuticals to Present at the JMP Securities Life Sciences Conference

Print
Font Size:
Default font size
Larger font size

Posted: Thursday, June 13, 2019 6:00 am

MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)--Jun 13, 2019--

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will be participating on a panel discussion entitled, “Innovative Treatment Approaches to Orphan CNS Developmental Disorders” at the JMP Securities Life Sciences Conference on Wednesday, June 19th, 2019 at 10:00 a.m. EDT. The panel will focus on novel pharmacological approaches to treating orphan genetic disorders that primarily impact the central nervous system.

About Newron Pharmaceuticals

Newron (SIX: NWRN) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The company is headquartered in Bresso near Milan, Italy. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the US, Australia, Canada, Brazil, and Colombia and is commercialized by Newron’s partner Zambon. US WorldMeds holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago® for Parkinson’s disease, Newron has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. For more information, please visit: www.newron.com

View source version on businesswire.com:https://www.businesswire.com/news/home/20190613005074/en/

CONTACT: Newron

Stefan Weber – CEO

+39 02 6103 46 26

pr@newron.com

UK/Europe

Julia Phillips / Natalie Garland-Collins, FTI Consulting

+44 20 3727 1000

SCnewron@fticonsulting.com

Switzerland

Martin Meier-Pfister, IRF

+41 43 244 81 40

meier-pfister@irf-reputation.ch

Germany/Europe

Anne Hennecke, MC Services

+49 211 52925222

anne.hennecke@mc-services.eu

USA

Paul Sagan, LaVoieHealthScience

+1 617 374 8800, Ext. 112

psagan@lavoiehealthscience.com

KEYWORD: UNITED STATES EUROPE NORTH AMERICA NEW JERSEY NEW YORK ITALY

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS PHARMACEUTICAL

SOURCE: Newron Pharmaceuticals S.p.A.

Copyright Business Wire 2019.

PUB: 06/13/2019 07:00 AM/DISC: 06/13/2019 07:00 AM

http://www.businesswire.com/news/home/20190613005074/en

© 2019 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Odessa, TX

Current Conditions

Clear
74°
Humidity: 26%
Winds: N at 2mph
Feels Like: 74°

Your Extended Forecast

Tomorrow

weather
High 99°/Low 68°
Mainly clear. Lows overnight in the upper 60s.

monday

weather
High 98°/Low 70°
Partly cloudy. Highs in the upper 90s and lows in the low 70s.

tuesday

weather
High 97°/Low 69°
Mostly sunny. Highs in the upper 90s and lows in the upper 60s.
Online Features

Pet Central

pets

Having a pet is a lot of responsibility, and we’ll help by giving you lots of tips and tricks! More >>

Fitness

Fitness

Our fitness articles will help teach you how to work out with gym- and home-based exercises. More >>

Crosswords

Crosswords

Enjoy the crosswords challenge in our free daily puzzles, from the harder Sunday crossword to the quicker daily. More >>

Sudoku

Sudoku

Every Sudoku has a unique solution that can be reached logically. Enter numbers into the blank spaces so that each row, column and 3x3 box contains the numbers 1 to 9. More >>




  • ALL-ACCESS: Subscribe to our e-edition and premium website at myoaoa.com.
    You can read your daily newspaper without taking a walk to the driveway.
    Look back at yesterday's newspaper, or issues from months ago with our archive feature.
    Call circulation at 432-337-7670 to sign up today.